Physician profile
Derek Ho
NPI 1265973689
$48,277.23
in general payments reported to CMS, 2019-2025
31 companies · $17K in 2025
The $17K reported for 2025 was more than what 93% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $40.86 · 2021: $133 · 2022: $1,500 · 2023: $8,011 · 2024: $21K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $21K · Consulting Fee: $17K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,387 · Travel and Lodging: $1,163 · Education: $202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $20,673.84 |
| Consulting Fee | $16,892.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,387.39 |
| Travel and Lodging | $1,162.96 |
| Education | $202.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $17,218.50 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $8,210.47 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $4,974.63 | 2022-2025 | Adbry, Anzupgo |
| Ucb, INC. | $2,659.73 | 2024-2025 | Bimzelx |
| Genzyme Corporation | $2,197.47 | 2019-2025 | |
| Abbvie INC. | $2,003.44 | 2020-2025 | |
| Galderma Laboratories, L.P. | $1,711.68 | 2022-2025 | Aklief, Nemluvio, Epsolay |
| Arcutis Biotherapeutics, INC. | $1,440.34 | 2023-2025 | Zoryve |
| Incyte Corporation | $1,297.00 | 2023-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $1,035.44 | 2022-2025 | Ilumya, Winlevi, Absorica Ld |
| Novartis Pharmaceuticals Corporation | $893.24 | 2022-2025 | |
| Dermavant Sciences, INC. | $690.76 | 2022-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $629.45 | 2023-2025 | Dupixent |
| Almirall LLC | $595.91 | 2023-2025 | Klisyri, Seysara |
| Lilly USA, LLC | $581.90 | 2022-2025 | Taltz, Olumiant, Ebglyss |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $548.06 | 2023-2025 | Tremfya |
| Amgen INC. | $306.87 | 2022-2025 | Otezla, Otezla |
| Mayne Pharma Commercial LLC | $240.97 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $225.84 | 2019-2021 | |
| Journey Medical Corporation | $218.02 | 2024-2025 | |
| Solta Medical, A Division of Bausch Health US, LLC | $115.71 | 2023 | |
| Merz North America, INC. | $99.52 | 2024 | |
| Organon LLC | $90.25 | 2025 | Vtama |
| Biofrontera INC. | $66.28 | 2023-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Botanix Sb INC | $51.86 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.35 | 2024 | Spevigo |
| Lnhc, INC | $40.34 | 2025 | Zelsuvmi |
| Regeneron Pharmaceuticals, INC. | $37.62 | 2024 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.66 | 2025 | Cabtreo, Siliq |
| Janssen Scientific Affairs, LLC | $17.59 | 2025 | Tremfya |
| Verrica Pharmaceuticals INC. | $16.33 | 2023 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Ho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.